Biocompatibility of a prolonged-action antialcohol preparation.
Acid and alkaline phosphatase activities in liver lysosomes and liver mitochondria, respectively, as well as in connective tissue capsule were studied for an antialcohol preparation (polyurethane carrier and disulfiram at 150, 300 and 625 mg/kg body weight) implanted subcutaneously. Increased acid phosphatase activity was observed in connective tissue capsule on days 14, 30 and 90 after implantation and in liver lysosome fraction on days 14 and 30 with preparation containing disulfiram at 300 and 625 mg/kg body weight. Alkaline phosphatase activity increased both in connective tissue capsule and in liver mitochondria up to day 30 only when sample with maximal disulfiram dose was implanted. Acid phosphatase activity is an adequate indicator for biocompatibility of prolonged-action medicine preparations. The data obtained show that the suggested medical form containing disulfiram 150 mg/kg body weight is biocompatible. Interaction between acid and alkaline phosphatase activity changes and biocompatibility and destruction of polymer implants is discussed.
Konoplitskaya
K L
KL
Institute of Organic Chemistry, Ukrainian Academy of Sciences, Kiev, USSR.
Pkhakadze
G A
GA
Narazayko
L F
LF
D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001672:Biocompatible Materials; D003238:Connective Tissue / Q000378:metabolism; D003692:Delayed-Action Preparations; D004221:Disulfiram / Q000008:administration & dosage*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004343:Drug Implants; D008099:Liver / Q000201:enzymology; D008422:Materials Testing; D011140:Polyurethanes; D051381:Rats
D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004343:Drug Implants; D011140:Polyurethanes; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D004221:Disulfiram